CO2022018389A2 - Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2), y usos de los mismos para propósitos de vacuna - Google Patents
Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2), y usos de los mismos para propósitos de vacunaInfo
- Publication number
- CO2022018389A2 CO2022018389A2 CONC2022/0018389A CO2022018389A CO2022018389A2 CO 2022018389 A2 CO2022018389 A2 CO 2022018389A2 CO 2022018389 A CO2022018389 A CO 2022018389A CO 2022018389 A2 CO2022018389 A2 CO 2022018389A2
- Authority
- CO
- Colombia
- Prior art keywords
- cov
- sars
- polypeptides
- inventors
- vaccine purposes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20305550 | 2020-05-26 | ||
| EP20306415 | 2020-11-20 | ||
| EP21305092 | 2021-01-26 | ||
| EP21305482 | 2021-04-12 | ||
| PCT/EP2021/064098 WO2021239838A2 (en) | 2020-05-26 | 2021-05-26 | Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022018389A2 true CO2022018389A2 (es) | 2023-02-06 |
Family
ID=76159441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0018389A CO2022018389A2 (es) | 2020-05-26 | 2022-12-19 | Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2), y usos de los mismos para propósitos de vacuna |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230212231A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4157343A2 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7858550B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230042222A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022024063A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3184802A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2022018389A2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022014943A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021239838A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108373509A (zh) * | 2009-03-10 | 2018-08-07 | 贝勒研究院 | 靶向抗原呈递细胞的抗病毒疫苗 |
| WO2022043551A2 (en) * | 2020-08-31 | 2022-03-03 | Curevac Ag | Multivalent nucleic acid based coronavirus vaccines |
| JP2024540505A (ja) * | 2021-11-17 | 2024-10-31 | アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル | ユニバーサルサルベコウイルスワクチン |
| CN114807179B (zh) * | 2022-06-01 | 2022-10-21 | 广州达博生物制品有限公司 | 一种新型冠状病毒肺炎疫苗的构建与应用 |
| WO2025023616A1 (ko) * | 2023-07-21 | 2025-01-30 | 세종대학교산학협력단 | 항 cd98 단일클론항체 및 이의 용도 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| WO1989012624A2 (en) | 1988-06-14 | 1989-12-28 | Cetus Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| AU8200191A (en) | 1990-07-09 | 1992-02-04 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | High efficiency packaging of mutant adeno-associated virus using amber suppressions |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| ATE237694T1 (de) | 1991-08-20 | 2003-05-15 | Us Gov Health & Human Serv | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| CN100588430C (zh) * | 2004-02-20 | 2010-02-10 | 复旦大学 | 基于表位的SARS-Cov基因疫苗及其构建 |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| EP2684889A3 (en) | 2007-02-02 | 2014-03-05 | Baylor Research Institute | Multivariable antigens complexed with targeting humanized monoclonal antibody |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2010009346A2 (en) | 2008-07-16 | 2010-01-21 | Baylor Research Institute | Hiv vaccine based on targeting maximized gag and nef to dendritic cells |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| BRPI1009454A2 (pt) * | 2009-03-10 | 2019-09-24 | Baylor Res Institute | vacinas contra o câncer direcionadas a células apresentadoras de antígenos |
| US8345509B2 (en) | 2009-04-16 | 2013-01-01 | Chevron U.S.A., Inc. | System and method to create three-dimensional images of non-linear acoustic properties in a region remote from a borehole |
| WO2011032161A2 (en) | 2009-09-14 | 2011-03-17 | Baylor Research Institute | Vaccines directed to langerhans cells |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| KR20130108295A (ko) | 2010-08-13 | 2013-10-02 | 베일러 리서치 인스티튜트 | 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제 |
| CA2813411C (en) | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| WO2014085580A1 (en) * | 2012-11-28 | 2014-06-05 | Baylor Research Institute | Methods and compositions involving a flu vaccine |
| RS57508B1 (sr) | 2013-09-06 | 2018-10-31 | Aurigene Discovery Tech Ltd | 1,2,4-derivati oksadiazola kao imunomodulatori |
| TR201811077T4 (tr) | 2013-09-06 | 2018-08-27 | Aurigene Discovery Tech Ltd | İmmünomodülatörler olarak 1,3,4-oksadiazol ve 1,3,4-tiyadiyazol türevleri. |
| US10849972B2 (en) * | 2018-11-27 | 2020-12-01 | King Adulaziz University | Trimeric S1-CD40L fusion protein vaccine against Middle East respiratory syndrome-coronavirus |
| IT202000009625A1 (it) * | 2020-04-30 | 2021-10-30 | Takis S R L | Polinucleotidi codificanti antigeni di sars-cov-2 e relativo uso in campo medico come vaccini. |
-
2021
- 2021-05-26 CA CA3184802A patent/CA3184802A1/en active Pending
- 2021-05-26 JP JP2022573138A patent/JP7858550B2/ja active Active
- 2021-05-26 US US17/927,804 patent/US20230212231A1/en active Pending
- 2021-05-26 WO PCT/EP2021/064098 patent/WO2021239838A2/en not_active Ceased
- 2021-05-26 BR BR112022024063A patent/BR112022024063A2/pt unknown
- 2021-05-26 MX MX2022014943A patent/MX2022014943A/es unknown
- 2021-05-26 KR KR1020227045248A patent/KR20230042222A/ko active Pending
- 2021-05-26 EP EP21728243.3A patent/EP4157343A2/en active Pending
-
2022
- 2022-12-19 CO CONC2022/0018389A patent/CO2022018389A2/es unknown
-
2025
- 2025-12-24 JP JP2025279763A patent/JP2026062799A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022024063A2 (pt) | 2023-01-31 |
| MX2022014943A (es) | 2023-03-08 |
| JP2023528017A (ja) | 2023-07-03 |
| WO2021239838A3 (en) | 2022-03-17 |
| KR20230042222A (ko) | 2023-03-28 |
| EP4157343A2 (en) | 2023-04-05 |
| JP2026062799A (ja) | 2026-04-10 |
| US20230212231A1 (en) | 2023-07-06 |
| WO2021239838A2 (en) | 2021-12-02 |
| CA3184802A1 (en) | 2021-12-02 |
| JP7858550B2 (ja) | 2026-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR122050A2 (es) | Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes | |
| BR112022024063A2 (pt) | Polipeptídeos de coronavírus 2 da síndrome respiratória aguda grave (sars-cov-2) e usos dos mesmos para fins de vacina | |
| CL2023000264A1 (es) | Nuevos vectores virales adeno-asociados dirigidos al hígado | |
| MX2019011599A (es) | Moleculas quimericas y usos de las mismas. | |
| CL2018000740A1 (es) | Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden | |
| PE20190563A1 (es) | Genes de mini-distrofina optimizados y casetes de expresion y su uso | |
| MX2019010275A (es) | Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de este. | |
| CL2024001715A1 (es) | Anticuerpo aislado que se une a la proteína e del virus del dengue; y uso. | |
| PE20081686A1 (es) | Proteinas de fusion que comprenden un antigeno prame (dage) | |
| EA033386B1 (ru) | Рекомбинантные иммуногенные полипептиды стеблевого домена гемагглютинина вируса гриппа а и их применение | |
| EA201891415A1 (ru) | Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения | |
| MX2017004664A (es) | Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria. | |
| AR102006A1 (es) | Vacunas recombinantes contra el virus de la fiebre aftosa (fmdv) y sus usos | |
| AR109528A1 (es) | Mutaciones estabilizantes de trímeros de proteínas de la envoltura del vih | |
| AR134554A2 (es) | Composición inmunológica o de vacuna y método para producir una respuesta protectora contra prrsv en un animal | |
| AR110632A1 (es) | Vectores del adenovirus canino | |
| MX345150B (es) | Antigenos ampliamente reactivos computacionalmente optimizados para virus de influenza h5n1 y h1n1. | |
| MX391149B (es) | Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion. | |
| MX387400B (es) | Células de mamífero que expresan antígenos de citomegalovirus. | |
| EA201790558A1 (ru) | Композиция с пониженной иммуногенностью | |
| CO2017011431A2 (es) | Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina | |
| CO2017001614A2 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
| MX2019007924A (es) | Vacunas contra la influenza. | |
| AR094725A1 (es) | Parvovirus 5a porcino, métodos de uso y vacuna | |
| MX2018008797A (es) | Vacunas contra el cancer. |